LQDA Liquidia Technologies, Inc.
Price Chart
Executive Summary
Liquidia reported Q1 2026 revenue of $132.9M (driven by YUTREPIA sales of $129.9M) and net income of $52.9M ($0.52 diluted EPS), marking its third consecutive profitable quarter. The strong commercial launch of YUTREPIA and cash generation provide a solid foundation, though ongoing litigation with United Therapeutics remains a key overhang.
Actionable Insight
The strong YUTREPIA launch and profitability trajectory support a bullish outlook, but monitor the ongoing patent litigation with United Therapeutics (UT) which could disrupt sales. Next catalysts include the Phase 3 Re-Spire study for L606 and any legal rulings.
Key Facts
- YUTREPIA net product sales of $129.9M in Q1 2026, up from $0 in Q1 2025
- Net income of $52.9M ($0.52 diluted EPS) vs net loss of $38.4M ($0.45 loss) in Q1 2025
- Adjusted EBITDA of $71.2M; cash and equivalents increased to $222.8M from $190.7M
- Over 4,500 unique patient prescriptions and ~3,750 patients started on YUTREPIA since launch
- Income tax expense of $3.9M recognized for the first time
Financial Impact
Revenue of $132.9M and net income of $52.9M in Q1 2026 represent a dramatic turnaround from the prior-year period, driven by YUTREPIA commercialization.
Risk Factors
- Adverse outcome in YUTREPIA patent litigation could halt sales
- Dependence on single product for revenue growth
- Potential for increased competition in inhaled prostacyclin market
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291703 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $65.50 awaiting T+1 | awaiting T+1 | — | $71.23 (+8.75%) |
|
Jun 10, 2026
4d ago
|
144
| $65.21 awaiting T+1 | awaiting T+1 | — | $71.23 (−9.23%) |
|
Jun 8, 2026
6d ago
|
Insider Cluster
| $63.94 awaiting T+1 | awaiting T+1 | — | $71.23 (+11.40%) |
|
Jun 8, 2026
6d ago
|
CLUSTER / 8-K
| $63.94 awaiting T+1 | awaiting T+1 | — | $71.23 (+11.40%) |
|
Jun 4, 2026
10d ago
|
144
| $62.76 awaiting T+1 | awaiting T+1 | — | $71.23 (−13.50%) |
|
Jun 4, 2026
10d ago
|
144
| $62.76 awaiting T+1 | awaiting T+1 | — | $71.23 (−13.50%) |
|
Jun 3, 2026
11d ago
|
Insider Cluster
| $62.54 $61.85 | ▼ −1.10% | ▲ +1.50% | $71.23 (+13.90%) |
|
Jun 1, 2026
13d ago
|
144
| $58.75 $55.11 | ▼ −6.20% | ▼ −6.34% | $71.23 (+21.24%) |
|
May 26, 2026
19d ago
|
Insider Cluster
| $62.03 $62.03 | · 0.00% | ▼ −0.55% | $71.23 (+14.83%) |
|
May 21, 2026
25d ago
|
Insider Cluster
| $61.97 $60.98 | ▼ −1.60% | ▼ −2.04% | $71.23 (+14.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access